HPV 31 poses a higher risk for developing cervical precancer than HPV 18, with results above the ASCCP’s 4% risk threshold for referral to colposcopy. Only an HPV assay with extended genotyping can individually identify high-risk HPV genotypes beyond HPV 16 and 18, including HPV 31.
The BD Onclarity™ HPV Assay is the only FDA-approved HPV assay that offers extended genotyping.
It provides an individual result for HPV 31and is FDA approved for the three most-common cervical cancer screening paradigms.
The BD Onclarity™ HPV Assay with extended genotyping allows for a more precise, accurate way to measure a woman’s risk for developing cervical precancer compared to an assay with partial genotyping.
Fill out the form below to read the brochure: